Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1258031

PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs


Palić, Jozefina; Božina, Tamara; Ganoci, Lana; Šimičević, Livija; Mucalo, Iva; Bićanić, Lucija Ana; Vrkić Kirhmajer, Majda; Samardžić, Jure
PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs // ESHG Pharmacogenetics Course : book of abstracts / Goričar, Katja (ur.).
Portorož: University of Ljubljana, Faculty of Medicine, 2022. str. 57-57 (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 1258031 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs

Autori
Palić, Jozefina ; Božina, Tamara ; Ganoci, Lana ; Šimičević, Livija ; Mucalo, Iva ; Bićanić, Lucija Ana ; Vrkić Kirhmajer, Majda ; Samardžić, Jure

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
ESHG Pharmacogenetics Course : book of abstracts / Goričar, Katja - Portorož : University of Ljubljana, Faculty of Medicine, 2022, 57-57

ISBN
978-961-267-220-1

Skup
ESHG Pharmacogenetics Course

Mjesto i datum
Portorož, Slovenija, 22.09.2022. - 24.09.2022

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
cardiovascular drugs ; drug safety ; interactions ; multidisciplinary ; pharmacogenetic ; risk factors ;

Sažetak
Introduction: This study aims to investigate pharmacogenomic variants, drug-drug-gene interactions and their relevance for predicting cardiovascular drugs’ adverse reactions (ADRs). Preliminary data from our prospective nested case- control study is presented here. Methods: The primary cohort consists of cardiovascular patients with new indications for direct oral anticoagulants (DOACs: apixaban, dabigatran etexilate, edoxaban, rivaroxaban) ; platelet aggregation inhibitors (PAI: clopidogrel, prasugrel, ticagrelor), statins (atorvastatin, fluvastatin, rosuvastatin, simvastatin). Patients have been recruited for 18 months. The cases represent subjects who developed ADRs during the follow-up period: bleeding/inefficiency from DOACs and PAIs, myotoxicity/hepatotoxicity from statins, and other serious ADRs. Controls are subjects with no ADRs presented during the follow-up period recruited from the same cohort. The relevant ADME gene variants are continuously genotyped: CYP2C9*2*3, CYP2C19*2*3*17, CYP2D6*3*4*5*6*9*10*41, CYP2J2*7, CES1 (rs2244613, rs8192935), CYP3A4*1B*22, CYP3A5*3, ABCB1 (c.1236C>T, c.2677G>T/A, c.3435C>T, rs4148738), ABCG2 c.421C>A, SLCO1B1 c.521T>C, depending on the subjects’ therapy. Clinical and laboratory parameters are also monitored. The Lexicomp® Clinical Decision Support System is used for drug-drug interactions (DDI) analysis. Results: Currently 660 patients are recruited (female=312, male=348), with cardiovascular drugs prescribed as follows: DOACs (n=318), PAIs (n=117), statins (n=386). 450 samples are genotyped according to prescribed drug-substrates: CYP2C9 (n=280 ; 42%), CYP2C19 (n=354 ; 54%), CYP3A4*22 (n=548 ; 83%), CYP3A5 (n=421 ; 64%), CYP2D6 (n=114 ; 17%), CYP2J2*7 (n=109 ; 17%), CES1 (n=31 ; 4.7%), ABCB1 (n=344 ; 52%), ABCG2 (n=525 ; 80%), and SLCO1B1 (n=366 ; 55%). 300 subjects are evaluated for potential DDIs with increased risk for ADRs, and found in group of statins (n=39/182 ; DDI level C=15% ; D=2%), DOACs (n=133/135, DDI level C=21%, D=26%) and PAIs (n=68/76, DDI level C=71%, D=2.6%). Conclusions: The preliminary data of the study points out that drug-drug-gene interactions and genetic polymorphisms may be important risk factors for cardiovascular ADRs.

Izvorni jezik
Engleski

Znanstvena područja
Interdisciplinarne prirodne znanosti, Kliničke medicinske znanosti, Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Projekti:
HRZZ-UIP-2020-02-8189 - Uloga farmakogenomike u predviđanju nuspojava kardiovaskularnih lijekova (PGx-CardioDrug) (Božina, Tamara, HRZZ - 2020-02) ( CroRIS)

Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Poveznice na cjeloviti tekst rada:

ibk.mf.uni-lj.si

Citiraj ovu publikaciju:

Palić, Jozefina; Božina, Tamara; Ganoci, Lana; Šimičević, Livija; Mucalo, Iva; Bićanić, Lucija Ana; Vrkić Kirhmajer, Majda; Samardžić, Jure
PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs // ESHG Pharmacogenetics Course : book of abstracts / Goričar, Katja (ur.).
Portorož: University of Ljubljana, Faculty of Medicine, 2022. str. 57-57 (poster, međunarodna recenzija, sažetak, znanstveni)
Palić, J., Božina, T., Ganoci, L., Šimičević, L., Mucalo, I., Bićanić, L., Vrkić Kirhmajer, M. & Samardžić, J. (2022) PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs. U: Goričar, K. (ur.)ESHG Pharmacogenetics Course : book of abstracts.
@article{article, author = {Pali\'{c}, Jozefina and Bo\v{z}ina, Tamara and Ganoci, Lana and \v{S}imi\v{c}evi\'{c}, Livija and Mucalo, Iva and Bi\'{c}ani\'{c}, Lucija Ana and Vrki\'{c} Kirhmajer, Majda and Samard\v{z}i\'{c}, Jure}, editor = {Gori\v{c}ar, K.}, year = {2022}, pages = {57-57}, keywords = {cardiovascular drugs, drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, }, isbn = {978-961-267-220-1}, title = {PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs}, keyword = {cardiovascular drugs, drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, }, publisher = {University of Ljubljana, Faculty of Medicine}, publisherplace = {Portoro\v{z}, Slovenija} }
@article{article, author = {Pali\'{c}, Jozefina and Bo\v{z}ina, Tamara and Ganoci, Lana and \v{S}imi\v{c}evi\'{c}, Livija and Mucalo, Iva and Bi\'{c}ani\'{c}, Lucija Ana and Vrki\'{c} Kirhmajer, Majda and Samard\v{z}i\'{c}, Jure}, editor = {Gori\v{c}ar, K.}, year = {2022}, pages = {57-57}, keywords = {cardiovascular drugs, drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, }, isbn = {978-961-267-220-1}, title = {PGx-CardioDrug - The role of pharmacogenomics in the prediction of cardiovascular ADRs}, keyword = {cardiovascular drugs, drug safety, interactions, multidisciplinary, pharmacogenetic, risk factors, }, publisher = {University of Ljubljana, Faculty of Medicine}, publisherplace = {Portoro\v{z}, Slovenija} }




Contrast
Increase Font
Decrease Font
Dyslexic Font